{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T20:49:11Z","timestamp":1793566151755,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/CG2\/005e\/2022-SGH"],"award-info":[{"award-number":["NMRC\/CG2\/005e\/2022-SGH"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["HCSAINV23jul-0001"],"award-info":[{"award-number":["HCSAINV23jul-0001"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["MOH-SEEDFD22apr-0001"],"award-info":[{"award-number":["MOH-SEEDFD22apr-0001"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["U19AG024904"],"award-info":[{"award-number":["U19AG024904"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001350","name":"Ministry of Health -Singapore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001350","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.tjpad.2025.100264","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T12:31:55Z","timestamp":1751545915000},"page":"100264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["A modelling approach to derive population-specific cutoff for plasma p-Tau217"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1555-7752","authenticated-orcid":false,"given":"Tau Ming","family":"Liew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.tjpad.2025.100264_bib0001","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","article-title":"Blood biomarkers for Alzheimer's disease in clinical practice and trials","volume":"3","author":"Hansson","year":"2023","journal-title":"Nat Aging"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100264_bib0002","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's Disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100264_bib0003","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"Jama"},{"issue":"10","key":"10.1016\/j.tjpad.2025.100264_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanhl.2024.07.013","article-title":"Challenges in the practical implementation of blood biomarkers for Alzheimer's disease","volume":"5","author":"Sch\u00f6ll","year":"2024","journal-title":"Lancet Healthy Longev"},{"key":"10.1016\/j.tjpad.2025.100264_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2024.100056","article-title":"Cutting through the noise: a narrative review of Alzheimer's disease plasma biomarkers for routine clinical use","author":"Sch\u00f6ll","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"issue":"7","key":"10.1016\/j.tjpad.2025.100264_bib0006","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","article-title":"Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's Disease","volume":"20","author":"Schindler","year":"2024","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100264_bib0007","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00415-025-12897-5","article-title":"Accuracy and clinical applicability of plasma tau 181 and 217 for Alzheimer's disease diagnosis in a memory clinic cohort","volume":"272","author":"Sarto","year":"2025","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100264_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2024.100027","article-title":"Core blood biomarkers of Alzheimer's disease: a single-center real-world performance study","volume":"12","author":"Pozzi","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100264_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105405","article-title":"Detection and staging of Alzheimer's disease by plasma pTau217 on a high throughput immunoassay platform","volume":"109","author":"Feizpour","year":"2024","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100264_bib0010","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70038","article-title":"Diagnostic accuracy of plasma p-tau217\/A\u03b242 for Alzheimer's disease in clinical and community cohorts","volume":"21","author":"Wang","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100264_bib0011","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13195-025-01719-5","article-title":"Diagnostic performance of plasma p-tau217 in a memory clinic cohort using the Lumipulse automated platform","volume":"17","author":"Mart\u00ednez-Dubarbie","year":"2025","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100264_bib0012","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13195-024-01513-9","article-title":"Diagnostic performance of plasma pTau(217), pTau(181), a\u03b2(1-42) and a\u03b2(1-40) in the LUMIPULSE automated platform for the detection of Alzheimer disease","volume":"16","author":"Arranz","year":"2024","journal-title":"Alzheimers Res Ther"},{"issue":"9","key":"10.1016\/j.tjpad.2025.100264_bib0013","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.1002\/alz.14140","article-title":"Optimizing cutpoints for clinical interpretation of brain amyloid status using plasma p-tau217 immunoassays","volume":"20","author":"Figdore","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100264_bib0014","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03622-w","article-title":"Plasma phospho-tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platform","author":"Palmqvist","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100264_bib0015","article-title":"Clinical performance of the fully automated Lumipulse plasma p-tau217 assay in mild cognitive impairment and mild dementia","volume":"17","author":"Dyer","year":"2025","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.1016\/j.tjpad.2025.100264_bib0016","unstructured":"Food and Drug Administration. FDA clears first blood test used in diagnosing Alzheimer\u2019s disease. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease. Published 2025. Accessed 21 May 2025."},{"issue":"1","key":"10.1016\/j.tjpad.2025.100264_bib0017","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12987-025-00620-5","article-title":"Exploring the ability of plasma pTau217, pTau181 and beta-amyloid in mirroring cerebrospinal fluid biomarker profile of Mild Cognitive Impairment by the fully automated Lumipulse(\u00ae) platform","volume":"22","author":"Catania","year":"2025","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.tjpad.2025.100264_bib0018","series-title":"510(k) Premarket notification","year":"2025"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100264_bib0019","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14585","article-title":"Influence of cognitive impairment and race on plasma p-tau(217) in two diverse cohorts","volume":"21","author":"Nayyar","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100264_bib0020","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3343\/alm.2023.43.1.55","article-title":"Indirect method for estimation of reference intervals of inflammatory markers","volume":"43","author":"Kang","year":"2023","journal-title":"Ann Lab Med"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100264_bib0021","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13195-016-0233-7","article-title":"Unbiased estimates of cerebrospinal fluid \u03b2-amyloid 1-42 cutoffs in a large memory clinic population","volume":"9","author":"Bertens","year":"2017","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100264_bib0022","doi-asserted-by":"crossref","first-page":"378","DOI":"10.2967\/jnumed.111.090340","article-title":"Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects","volume":"53","author":"Joshi","year":"2012","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100264_bib0023","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13195-021-00836-1","article-title":"Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach","volume":"13","author":"Royse","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100264_bib0024","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/10705510701575396","article-title":"Deciding on the number of classes in latent class analysis and growth mixture modeling: a Monte Carlo simulation study","volume":"14","author":"Nylund","year":"2007","journal-title":"Structural Equation Modeling: A Multidisciplinary Journal"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100264_bib0025","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12877-018-0804-5","article-title":"Detecting pre-death grief in family caregivers of persons with dementia: measurement equivalence of the Mandarin-chinese version of Marwit-Meuser Caregiver Grief Inventory","volume":"18","author":"Liew","year":"2018","journal-title":"BMC Geriatr"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100264_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v028.i05","article-title":"Building predictive models in R using the caret package","volume":"28","author":"Kuhn","year":"2008","journal-title":"J Stat Softw"},{"key":"10.1016\/j.tjpad.2025.100264_bib0027","doi-asserted-by":"crossref","unstructured":"Van Lissa C.J. tidySEM: tidy structural equation modeling. R package version 0.2.1. https:\/\/github.com\/cjvanlissa\/tidySEM\/. Published 2019. Accessed 25 Feb 2025.","DOI":"10.32614\/CRAN.package.tidySEM"},{"key":"10.1016\/j.tjpad.2025.100264_bib0028","unstructured":"Canty A., Riplley B. boot: bootstrap R (S-Plus) functions. R package version 1.3-31. https:\/\/cran.r-project.org\/web\/packages\/boot\/index.html. Published 2024. Accessed 25 Feb 2025."}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725002079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725002079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:37:23Z","timestamp":1762673843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580725002079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2274580725002079"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100264","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A modelling approach to derive population-specific cutoff for plasma p-Tau217","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100264","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100264"}}